Home › Funds › Thrivent › Thrivent Healthcare Portfolio
Fund family: Thrivent · Filed by THRIVENT SERIES FUND INC (CIK 790166) · SEC series S000021867
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 541 with, 23 against, 0 abstentions (not counted as with management). Shareholder proposals: 3 FOR, 20 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Thrivent’s manager page (222,957 ballot items across 50 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Thrivent | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 97.3% | 527 | 93.8% | 192,489 |
| Backed environmental and social shareholder proposals at US companies | n/a | 7 | 1.2% | 2,125 |
Each ballot item this fund voted is set against the votes of the other Thrivent funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted the same way as most Thrivent funds on all 505 items where a comparison was possible.
The same votes as “with management” above, by the sector of the company voted on. 97.9% of this fund’s 564 such votes could be given a sector; the other 12 (2.1%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 497 | 22 | 4.4% |
| Industrials | 38 | 0 | 0.0% |
| Consumer Staples | 17 | 1 | 5.9% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 407 | 0 |
| Audit-related | 48 | 0 |
| Say-on-Pay | 44 | 0 |
| Corporate Governance | 26 | 15 |
| Compensation | 18 | 1 |
| Capital Structure | 12 | 0 |
| Other Social Issues | 4 | 4 |
| Environment or Climate | 3 | 3 |
| Shareholder Rights and Defenses | 3 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Eli Lilly and Company | May 4, 2026 | $46M | 10 | 2 |
| Johnson & Johnson | April 23, 2026 | $24M | 15 | 1 |
| AbbVie Inc. | May 8, 2026 | $21M | 8 | 1 |
| UnitedHealth Group Incorporated | June 1, 2026 | $17M | 12 | 1 |
| Merck & Co., Inc. | May 26, 2026 | $15M | 18 | 3 |
| Amgen Inc. | May 19, 2026 | $9M | 15 | 1 |
| Danaher Corporation | May 5, 2026 | $9M | 14 | 0 |
| Stryker Corporation | May 6, 2026 | $8M | 12 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | Against | For |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| April 23, 2026 | Johnson & Johnson | Independent Board Chair Shareholder proposal | Against | For |
| May 8, 2026 | AbbVie Inc. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | Against | For |
| June 1, 2026 | UnitedHealth Group Incorporated | If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| May 19, 2026 | Amgen Inc. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 23, 2026 | Pfizer Inc. | Adopt an Independent Chair Policy Shareholder proposal | Against | For |
| May 5, 2026 | Bristol-Myers Squibb Company | Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director Shareholder proposal | Against | For |
565 ballot items at 44 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Thrivent Healthcare Portfolio voted at 44 shareholder meetings of 44 companies, on 565 ballot items in all. Where management made a recommendation, the fund followed it on 95.9% of the items and voted against it 23 times. Its most frequent area of disagreement was corporate governance (15 of its votes against management). It voted on 23 shareholder proposals. It voted FOR the board's own proposals more often than Thrivent's funds as a whole (97.3% against 93.8%). It voted the same way as most Thrivent funds on every item where a comparison was possible.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Thrivent’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.